Werewolf Therapeutics, Inc. (HOWL) is a Biotechnology company in the Healthcare sector, currently trading at $0.92. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is HOWL = $1 (+9% upside).
Valuation: HOWL trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25).
Net income is $61M (loss), growing at -15.8%/yr. Net profit margin is 0% (thin). Gross margin is 3.8% (-80.9 pp trend).
Balance sheet: total debt is $9M against $25M equity (Debt-to-Equity (D/E) ratio 0.38, conservative). Current ratio is 1.62 (strong liquidity). Debt-to-assets is 13.6%. Total assets: $69M.
Analyst outlook: 9 / 9 analysts rate HOWL as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 88/100 (Pass), Income ?/100 (Fail).
